• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

How Has Cervical Cancer Incidence Changed Over the Past 10 Years in the US?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Incidence of cervical cancer may have plateaued between 2012 and 2017
  • A decline in cancer screening uptake has been reported, particularly among younger women
  • Shahmoradi et al. (JAMA, 2022) evaluated calendar trends in cervical cancer incidence by age at diagnosis 

METHODS:

  • Time series data analysis
  • Data
    • National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) from 2001 to 2019
  • Population
    • Cervical cancer cases
  • Study design
    • Hysterectomy-corrected incidence trends were assessed by removing the proportion of women with hysterectomy from the denominator
    • For age groups with increasing incidence, trends were examined by race and ethnicity, stage, and histology
  • Primary outcome
    • Incidence rates of cervical cancer
    • Trends in cases
    • Annual percentage changes (APCs) by 5-year age group

RESULTS:

  • 227,062 reported cervical cancer cases
  • Overall, hysterectomy-corrected cervical cancer incidence declined
    • 2001: 12.39 per 100,000
    • 2019: 9.80 per 100,000
    • APC −1.2% (95% CI, −1.6 to −0.9)
  • Among women aged 30 to 34 years, after an initial decline from 2001 to 2012, incidence increased after 2012
    • 2001: 12.77 per 100,000
    • 2012: 10.14 per 100,000
    • 2019: 11.60 per 100,000
    • 2001 to 2012: APC −2.3% (95% CI, −2.8 to −1.7)
    • 2012 to 2019: APC 2.5% (95% CI, 1.4 to 3.6)
  • Among this age group, hysterectomy-corrected cervical cancer incidence increased significantly for
    • Hispanic
      • APC 3.0% (95% CI, 0.3 to 5.7)
    • Non-Hispanic White
      • APC 2.8% (95% CI, 0.6 to 5.0)
    • Other racial and ethnic groups
      • APC 5.0% (95% CI, 2.7 to 7.4)
  • The APC for Black women was relatively stable from 2012 to 2019
    • APC −0.8% (95% CI, −2.8 to 1.2)
  • Increases occurred for
    • Localized stage cervical cancer
      • APC 2.8% (95% CI, 1.3 to 4.3)
    • Regional stage cervical cancer
      • APC 1.9% (95% CI, 0.7 to 3.1)
    • Squamous cell carcinoma
      • APC 2.6% (95% CI, 1.0 to 4.2)
    • Adenocarcinoma
      • APC 3.0% (95% CI, 0.9 to 5.1)

CONCLUSION:

  • Cervical cancer rates declined or were stable from 2012 to 2019, except among women aged 30 to 34
    • Among this age group the incidence increased by 2.5% per year after 2012

Possible Explanations for the Increased Incidence Include Guideline Changes in 2012

  • Co-testing (HPV and cytology): Could lead to increased detection of early-stage cancers 
  • Increased screening interval: The authors state

In 2012, the US Preventive Services Task Force recommended an increase in screening interval in 21- to 65-year-old women with cytology every 3 years or in 30- to 65-year-old women with a combination of cytology and human papillomavirus testing every 5 years

Beginning in 2013, declines in screening participation among 21- to 29-year-old women were observed

Future studies are needed to assess factors that underlie the increase in cervical cancer incidence among 30- to 34-year-old women

Learn More – Primary Sources:

Cervical Cancer Incidence Among US Women, 2001-2019

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Have Distant Stage Cervical Cancer Trends in the US Changed Over the Past 18 Years?
Impact of Disparities on Uptake of USPSTF Cancer Screening Recommendations

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site